ClinicalTrials.gg
RecruitingNCT05710692RISEUpdated Mar 18, 2026

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

A Phase 2/3 interventional study of PRX-102 1 mg/kg every 2 weeks and PRX-102 2 mg/kg every 4 weeks in Fabry Disease, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 10 sites in Japan. Open to participants aged 13 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
13 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing pegunigalsidase alfa in Fabry Disease — 2 open to participants now, 2 under way, 2 of them phase 3. pegunigalsidase alfa · Fabry Disease.

Planned enrollment
8th of 10
16 · median 22
Started
2023
the only one that year
Phase 2/3
2 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
4 of 10
Chiesi Farmaceutici S.p.A.

Among the 10 studies testing pegunigalsidase alfa in Fabry Disease, this one is the 8th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 2/3, and was the 9th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 10 studies testing pegunigalsidase alfa in Fabry Disease are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pegunigalsidase alfa

pegunigalsidase alfa: first FDA approval 2023 (ELFABRIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 13 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegunigalsidase alfa in Fabry Disease, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.

Read the detailed description

Investigators are doing this study to find out if treatment with pegunigalsidase alfa will prevent or reduce the development of health problems caused by Fabry disease and thereby improve patients' health and quality of life.

pegunigalsidase alfa (PRX-102) is a drug made using genetic engineering techniques and manufactured using cultured tobacco cells. It is given by intravenous infusion every 2 weeks, at a dosage of 1 milligram per kilogram (mg/kg) of body weight.

The study consists of a main study that is divided into two stages, each of which will last one year, followed by an optional extension study. In stage II of main study and in the optional extension study, the participants may receive PRX-102 intravenous infusion every 2 weeks, at a dosage of 1 milligram per kilogram (mg/kg) of body weight or every 4 weeks at a dosage of 2 milligrams per kilogram (mg/kg) of body weight.

There are three groups (cohorts) in this study, with adults enrolled in either Cohort A or B and adolescents in Cohort C. Whether an adult is assigned to Cohort A or Cohort B depends on their kidney function and treatment history.

This study will start with a screening visit of up to 6 weeks. It will be followed up by infusion visits every 2 weeks or 4 weeks. For subjects not continuing in the extension stage, a follow-up call is to be made 30 days after the last study drug infusion.

03

Conditions studied

  • Fabry Disease

Browse trials for

04

Who can participate

Ages eligible
13 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have been born in Japan and have their biological parents and all 4 grandparents of Japanese descent
  2. A documented diagnosis of Fabry disease, as determined by the following:

    • Males: Plasma and/or leukocyte alpha-galactosidase-A activity (by activity assay) that is ≤ 5% of mean normal laboratory levels or, if the enzymatic activity is above the 5% limit but still under the normal level, a confirmed disease-causing mutation of the GLA gene
    • Females: Historical genetic test results consistent with Fabry mutations or, in the case of novel mutations, a first-degree male relative with Fabry disease
    • All subjects: At least one of the following characteristic features of Fabry disease: neuropathic pain, cornea verticillata, and/or clustered angiokeratoma
  3. Estimated (eGFR) at screening ≥40 mL/min/1.73 m2. For adults, this will be calculated using the Japanese Modified Chronic Kidney Disease Epidemiology Collaboration (JPN-CKD-EPI) Creatinine equation (2009); and for adolescents, it will be calculated using the Creatinine Cystatin C-based Chronic Kidney Disease in Children (CKiD) equation.
  4. Clinical condition that in the opinion of the Investigator requires treatment with ERT
  5. A female subject (including an adolescent in Cohort C, if applicable) must meet one of the following criteria:

    • If of , she must:

      • Have a negative serum pregnancy test result at screening, AND
      • Agree to undergo a urine pregnancy test at baseline and every 12 weeks thereafter up to the final treatment, AND
      • Agree to use one of the following highly reliable methods of from the day of the signature until 30 days after the last infusion received. The following methods are acceptable:

        • Placement of an intrauterine device (IUD) or intrauterine system (IUS)
        • Combined (both oestrogen and progestogen) hormonal contraception (oral) associated with inhibition of ovulation, supplemented with a barrier method (preferably male condom)
        • Bilateral tubal occlusion
        • Sexual abstinence, defined as refraining from heterosexual intercourse during the entire study period
        • Partner vasectomy, provided that the partner is the sole sexual partner and has received medical verification of the surgical success
    • Be of non-childbearing potential, defined as one of the following:

      • (12 consecutive months of amenorrhea), OR
      • Permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy (supporting evidence required)

Additional inclusion criteria for subjects in Cohort A

For subjects enrolled in Cohort A, these specific inclusion criteria, in addition to those above, apply:

  • Aged ≥18 to ≤70 years
  • Treatment with agalsidase beta or agalsidase alfa for at least the last 12 months prior to screening, with the dose stable (defined as having received at least 80% of the labelled dose) for at least the last 6 months
  • Diagnosis of kidney impairment, defined as a linear slope of eGFR more negative than or equal to -2 mL/min/1.73 m2/year. The historical eGFR slope will be calculated based on at least 3 serum creatinine values obtained over the 9 to 24 months prior to screening, using the JPN-CKD-EPI Creatinine equation (2009). This criterion will be confirmed at screening by calculating the screening eGFR slope using historical and screening serum creatinine values. Both historical and screening eGFR slopes will be used for the diagnosis of kidney impairment.

Additional inclusion criterion for subjects in Cohort B

For subjects enrolled in Cohort B, this specific inclusion criterion, in addition to those above, applies:

- Aged ≥18 to ≤70 years

Additional inclusion criteria for subjects in Cohort C

For subjects enrolled in Cohort C, these specific inclusion criteria, in addition to those above, apply:

  • Aged ≥13 to \<18 years
  • Subjects who have previously received or are currently receiving ERT treatment, must be negative for ADAs to PRX-102

Exclusion criteria

Exclusion Criteria:

  1. Administration of ERT for Fabry disease within 14 days before baseline, substrate reduction therapy for Fabry disease within 3 days before baseline, or chaperone therapy for Fabry disease within 3 days before baseline
  2. History of type I reactions (anaphylactic or anaphylactoid life-threatening reaction) to other ERT treatment for Fabry disease or to any component of the study drug
  3. Cohort A only: value of >90 to ≤120 mL/min/1.73 m2 at screening and a historical eGFR value >120 mL/min/1.73 m2 in the 9 to 24 months before screening, indicating absence of renal impairment. eGFR to be calculated using the JPN-CKD-EPI creatinine equation (2009).
  4. Urine protein to creatinine ratio (UPCR) >0.5 g/g (0.5 mg/mg or 500 mg/g) if not treated with an ACE inhibitor or ARB
  5. Initiation of treatment, or a change in dose to ongoing treatment, with an angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in the 4 weeks prior to screening.
  6. Currently taking another drug for any condition
  7. Carry only known non-pathogenic Fabry mutations
  8. History of renal dialysis or kidney transplantation
  9. History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and renal vasculitis); non-specific conditions (e.g., ischemia, toxic injury); or extrarenal pathology (e.g., prerenal azotaemia, and acute postrenal obstructive nephropathy
  10. History of (or current) requiring treatment; the one exception is a prior history of resected basal cell carcinoma
  11. Severe cardiomyopathy or significant unstable cardiac disease within 6 months prior to screening
  12. A positive test for Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) within 3 months prior to screening, using a validated molecular assay or validated antigen assay
  13. Females: Pregnant or lactating, or of with a fertile male partner and unwilling to use a highly reliable method of from the signature until 30 days after the last infusion received
  14. Presence of any medical, emotional, behaevioral, or psychological condition that in the judgment of the Investigator could interfere with the subject's compliance with the requirements of the study
  15. Previous treatment with cellular therapy or gene therapy for any condition
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks

    PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks (available only in the optional extension part)

    Drug: PRX-102 1 mg/kg every 2 weeks · Drug: PRX-102 2 mg/kg every 4 weeks

Interventions

  • DrugPRX-102 1 mg/kg every 2 weeks

    Drug page: Pegunigalsidase alfa

    PRX-102 1 mg/kg every 2 weeks

    Also known as: pegunigalsidase alfa, Recombinant human alpha galactosidase-A

  • DrugPRX-102 2 mg/kg every 4 weeks

    Drug page: Pegunigalsidase alfa

    PRX-102 2 mg/kg every 4 weeks

    Also known as: pegunigalsidase alfa, Recombinant human alpha galactosidase-A

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  2. Incidence of Infusion Related Reactions (IRRs)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  3. Incidence of Injection site reactions (ISRs)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  4. Change of laboratory tests' results

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  5. Change in in body weight in kilograms

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  6. Change in height in centimeters

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  7. Change in Tanner stage

    Tanner Staging of Sexual Development will be used to assess sexual development (i.e. breast development (B1 to B5) and pubic hair development (Ph-1 to Ph-5) in females and pubic hair and genetical development (G1-G5) in males.

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  8. Change from baseline of 12-lead ECG quantitative parameters: Mean Heart Rate, PR Interval, QRS Duration, QT Interval, QTc Interval, and ST Segment

    Quantitative ECG parameters will be summarized by cohort and overall

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  9. Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  10. ADA status change from baseline

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  11. Incidence of premedication use at each visit and change of infusion premedications from baseline

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  12. Change from baseline of Maximum plasma concentration (Cmax), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  13. Change from baseline of Time to maximum plasma concentration (tmax), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  14. Change from baseline of Area under the plasma concentration-time curve from time 0 to time t (AUC0 t), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  15. Change from baseline of Area under the curve from time 0 to 2 weeks (AUC0-2wk), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  16. Change from baseline of Area under the curve from time 0 to infinity (AUC0-∞), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  17. Change from baseline of Terminal half-life (t1/2), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  18. Change from baseline of Area under the curve over a dosing interval (AUCτ), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  19. Change from baseline of Observed drug concentration at the end of the dosing interval (Cτ), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  20. Change from baseline of Clearance (Cl), pharmacokinetic parameter

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

  21. Change from baseline of Volume of distribution (Vz), pharmacokinetic parameters

    Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)

Other outcomes

  1. Change in eGFR

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  2. Change in annualized eGFR slope

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  3. Change in urine albumin levels

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  4. Change in urine protein levels

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  5. Incidence of changes in echocardiogram results

    Systolic and diastolic heart function and structure is assessed by ultrasound of the heart. Echocardiogram parameters include left ventricular mass index (LVMi), ejection fraction, fractional shortening, left ventricular mass, valve abnormalities and thickness.

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  6. Incidence of changes in Holter ECG

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  7. Change of cardiac biomarkers

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  8. Adults only: Response of the heart to external stress induced by exercise measured with Stress test (Bruce protocol)

    Qualitative evaluation (yes/no) of symptoms (chest pain, shortness of breath, dizziness, palpitations, and other) and the overall impression: normal stress test (yes/no) will be summarized. For overall impression only, a shift from baseline will be presented: normal stress test (yes / no).

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  9. Adults only: change of Cardiac MRI

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  10. Adults only: change of Brain MRI

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  11. Change in plasma level of Gb3 concentration (nM)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  12. Change in plasma level of lyso-Gb3 (nM)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  13. Change in urine level of lyso-Gb3 (nM)

    Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)

  14. Change from baseline of Mainz Severity Score Index (MSSI) scores

    Domains (general, neurological, cardiovascular, renal dysfunction)

    Time frame: 12 Months, 24 Months and at the end of study

  15. Incidence of change from baseline in the number of different pain medications

    Time frame: 12 Months, 24 Months and at the end of study

  16. Incidence of Fabry Clinical Events

    FCEs are classified into four categories: renal, cardiac, cerebrovascular and death due to non-cardiac reasons

    Time frame: 12 Months, 24 Months and at the end of study

  17. Adults only: change in Gastrointestinal Symptom Rating Scale (GSRS) scores

    To measure common symptoms of gastrointestinal disorders.

    Time frame: 12 Months, 24 Months and at the end of study

  18. Adults only: change in Brief Pain Inventory - Short Form (BPI-SF) scores

    Time frame: 12 Months, 24 Months and at the end of study

  19. Adults only: change of quality of life assessed using EQ-5D-5L questionnaire

    Time frame: 12 Months, 24 Months and at the end of study

  20. Cohort C only: Change in Gastrointestinal Symptoms (PedsQL-GI) Questionnaire scores

    To measure common symptoms of gastrointestinal disorders.

    Time frame: 12 Months, 24 Months and at the end of study

  21. Cohort C only: change in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) scores

    Time frame: 12 Months, 24 Months and at the end of study

  22. Cohort C only: change in PedsQL Pediatric Pain Questionnaire (PedsQL-PPQ) scores

    Time frame: 12 Months, 24 Months and at the end of study

  23. Cohort C only: change of quality of life assessed using EQ-5D-Y Questionnaire

    Time frame: 12 Months, 24 Months and at the end of study

07

Study locations

8 of 10 sites recruiting
  • Fukuoka University Chikushi Hospital
    Chikushino-shi, Fukuoka 818-8502, Japan
    Withdrawn

    Not enrolling at this site.

  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
    Recruiting
    • Saori Yamamoto · Contact
    • Saori Yamamoto · Principal investigator
  • University of the Ryukyu Hospital
    Nishihara, Okinawa 903-0125, Japan
    Recruiting
    • Koichi Nakanishi · Contact
    • Koichi Nakanishi · Principal investigator
  • Osaka University Hospital
    Suita, Osaka 565-0871, Japan
    Recruiting
    • Tomoko Namba · Contact
    • Tomoko Namba · Principal investigator
  • Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo
    Bunkyo-ku, Tokyo 113-0033, Japan
    Recruiting
    • Takao Kato · Contact
    • Takao Kato · Principal investigator
  • Tokyo Jikei University Hospital
    Minato-ku, Tokyo 105-8461, Japan
    Recruiting
    • Masahisa Kobayashi · Contact
    • Masahisa Kobayashi · Principal investigator
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
    Recruiting
    • Hiroyuki Yamakawa · Contact
    • Hiroyuki Yamakawa · Principal investigator
  • Asahikawa Medical University Hospital
    Asahikawa, Japan
    Recruiting
    • Naoki Nakagawa · Contact
    • Naoki Nakagawa · Principal investigator
  • Niigata University Medical & Dental Hospital
    Niigata, 951-8520, Japan
    Recruiting
    • Hirofumi Watanabe · Contact
    • Hirofumi Watanabe · Principal investigator
  • National Hospital Organization Okayama Medical Center
    Okayama, Japan
    Not yet recruiting
    • Mahoko Furujo · Contact
    • Mahoko Furujo · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Feb 2, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Oct 2027
CompletionEst.
Aug 2029
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05710692
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Feb 2, 2023
Start date
Aug 1, 2023
Primary completion
Oct 2027 (estimated)
Completion
Aug 2029 (estimated)
Last update
Mar 18, 2026

Study contacts

Chiesi Clinical Trial
Contact
clinicaltrials_info@chiesi.com
+3905212791

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegunigalsidase alfa

Start the discussion